Advair Bioequivalence Guidance Falls Short of GSK’s Requests

FDA’s draft guidance requires clinical study but sets a lower bar to generics of GSK’s blockbuster asthma and COPD treatment than company proposed; standards appear poised for warm reception from generic challengers.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America